Mr. Christopher Viehbacher is president and CEO of Biogen, a multinational biotechology company. He is also a founding partner of Gurnet Point Capital, a Boston-based investment fund associated with the Bertarelli family with a $2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc; the Chairman of Vedanta, a Pure Tech portfolio company; and a member of the Board of Trustees of Northeastern University.Mr. Viehbacher is the former CEO and member of the board of directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.Prior to joining Sanofi, Mr. Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a member of the board of directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. He began his career with Price Waterhouse after graduating with a degree in Commerce at Queen’s University in Canada.Mr. Viehbacher has been a strong advocate for the health care industry. Current and past advocacy roles include: Former Co-chair with Bill Gates for the CEO Roundtable on Neglected Diseases, Immediate Past Chairman of the CEO Roundtable on Cancer, Past Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington, and President of the European Federation of Pharmaceutical Industries and Associations in Brussels. He was Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living and Member of the International Business Council.Mr. Viehbacher has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario. He has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide, and France’s highest civilian honor, the Legion d’Honneur.

Dr. David M. Reese is executive vice president, Research and Development. In this role, Dr. Reese oversees Discovery Research, Global Development, Global Regulatory Affairs and Safety, as well as Global Medical. Dr. Reese joined Amgen in 2005 and has served in various leadership roles within the Research and Development organization. This includes most recently serving as Senior Vice President of Translational Sciences and Oncology where he oversaw the translation of Amgen’s medicines from the lab into the clinic and the overall oncology strategy.Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization. Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

As the CEO of SAS, the world’s leading business analytics software vendor, Jim Goodnight has led the company since its inception in 1976, overseeing an unbroken chain of revenue growth and profitability unprecedented in the industry. He is recognized globally for being a trailblazer among companies that top great workplace rankings, including being No.1 on several country and multinational lists. Harvard Business School named Goodnight a Great American Business Leader, and he was named one of America’s 25 Most Fascinating Entrepreneurs by Inc. magazine. A champion of education reform, Goodnight sees education as critical to the success of individuals, organizations and nations.

John co-founded Hatteras in 2000 after a successful career as a technology entrepreneur. After a decade in politics and public policy, he was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing. Following E-Comm’s acquisition by XcelleNet, Inc. (XNET), John ran the services division there until the company was acquired by Sterling Commerce (SE). Following the acquisition John founded Hatteras with Clay Thorp.At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations.With his partners at Hatteras John has helped build a seed and early stage venture capital partnership with over $600 million under management in six funds. In that time, he has served on the boards of Synthematix, a chemistry informatics company that was acquired by Symyx Technologies (SMMX); Clinverse, a financial lifecycle management technology provider to contract research organizations (CROs) and pharmaceutical companies, acquired by Bioclinica, Inc.; Bivarus, a survey-based health analytics company acquired by Press Ganey; NurseGrid, the nation’s most widely distributed nurse scheduling platform, acquired by HealthStream; and Medfusion, a leading patient engagement platform, acquired by NextGen. John currently serves on the boards of Iris Healthcare, Elligo Health Research, Wildflower Health, Jumo Health, and as an observer at SafeRide and Clinipace Worldwide. He holds an A.B. from Harvard University.COMMUNITY AND BOARD ENGAGEMENTS:Throughout his career John has been active in government and public policy at the state and federal levels. A recipient of the Lyndhurst Prize, John served on the N. C. Economic Development Board, the state’s Clean Water Management Trust Fund board of directors, the Council for Entrepreneurial Development, and as a trustee of the University of North Carolina School of the Arts. He currently serves as a longstanding board leader at SouthLight Healthcare, a non-profit provider of substance use treatment and mental health services, on the board of the North Carolina Wildlife Federation, and on the national advisory board of Organizing for Action. He is active at White Memorial Presbyterian Church and an enthusiastic member of the OnPoint House Band that plays for worship every Sunday. He has also been a member of the Americana band, Bloomsbury, for over 30 years and plays banjo in the Southern String Band.

Since 2009, Major General Granger has been the President and CEO of THE 5Ps, LLC, a health care, education, and leadership consulting organization in Colorado. Prior to his retirement from the US Army in 2009, Dr. Granger served as the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, DC.In that role, he was the principal advisor on health plan policy and performance at the Department of Defense. His experience, background, training, and expertise has required the building of strong, value-based relationships. He acquires clear guidelines to assess and determine “best value” and determines a process to ensure clear requirements and criteria to manage relationships to measurable, accountable outcomes.Dr. Granger oversaw the acquisition, operation, and integration of TRICARE/DOD’s managed care program within the Military Health System, leading a staff of 1,800 in planning, budgeting, and executing a $22.5 Billion Defense Health Program.Prior to joining TRICARE Management Activity, MG Granger led the largest U.S. and multi-national battlefield health system in our recent history while serving as Commander, Task Force 44th Medical Command and Command Surgeon for the Multinational Corps Iraq. He has led at every level of the Army Medical Department, with previous assignments across the United States, Europe, and Iraq.Dr. Granger has received numerous awards, decorations, and honors, including the Defense Superior Service Medal, the Legion of Merit with three oak leaf clusters, the Bronze Star Medal, and the Meritorious Service Medal with four oak leaf clusters. He is board-certified by the American Board of Internal Medicine and the Board of Hematology and Oncology, certified Physician Executive by the Certifying Commission in Medical Management, certified by the American College of Healthcare Executives, and Certified in Medical Quality by the American Board of Medical Quality. CERT-certificate in Cybersecurity Oversight from Carnegie Mellon University, certified in Healthcare Compliance by HCCA and is a certified Compliance Officer by AAPC.

Dr. Sharpless led the National Cancer Institute (NCI) from 2017 to 2022. He was appointed acting commissioner of the U.S. Food and Drug Administration (FDA) in 2019 and served for seven months before returning to his position at the NCI. Prior to his government service, Sharpless was the director of the University of North Carolina – Chapel Hill’s Lineberger Comprehensive Cancer Center from 2014 until 2017.An experienced cancer researcher, Sharpless is renowned for his discoveries related to cell aging. He founded G1 Therapeutics, which developed the FDA-approved medicine Cosela (Trilaciclib), used to prevent chemotherapy toxicity. He is a member of the American Association for Cancer Research Academy, the Association of American Physicians, the American Society for Clinical Investigation and the National Academy of Medicine.A native of Greensboro, N.C., Sharpless earned an undergraduate degree in mathematics and a medical degree from the UNC-Chapel Hill. He completed his residency training at Massachusetts General Hospital and his clinical and research fellowship in hematology and oncology at Dana-Farber/Partners Cancer Care in Boston. He returned to Chapel Hill to accept a faculty appointment at the Lineberger Center in 2002.

Peter WT Pisters, M.D., took the helm as president of The University of Texas MD Anderson Cancer Center in 2017, and forged a new path forward to end cancer by transforming the culture of the nation’s top-ranked cancer center. With a boundless appetite for listening and learning, Dr. Pisters has built an inclusive environment within the organization while also prioritizing relationships with government, industry and community partners to thrive in the rapidly changing health care landscape.A renowned cancer surgeon, researcher, professor and administrator, Dr. Pisters established his career at MD Anderson, serving over 20 years as a faculty member and medical director for the center’s expansion in metropolitan Houston. He left MD Anderson to serve as president and CEO of the University Health Network in Toronto, Canada’s largest academic medical center, before returning to MD Anderson in 2017. He says the privilege of caring for cancer patients was the most impactful preparation he has had for his current role.With MD Anderson’s 22,000+ employees as his priority, Dr. Pisters has cultivated a diverse executive team and championed programs and continuous growth for all. He was named a Top CEO by Glassdoor in 2018 and 2019 – the only health care leader in Texas to make the top 100 list.Dr. Pisters earned his medical degree at the Schulich School of Medicine and Dentistry at the University of Western Ontario in Canada and did postgraduate work at Memorial Sloan Kettering Cancer Center in New York. He received a master’s degree in health care management at the Harvard T.H. Chan School of Public Health in Boston.

Scott White is Company Group Chairman, North America, at the Janssen Pharmaceutical Companies of Johnson & Johnson. A member of the Pharmaceuticals Group Operating Committee, he is responsible for leading Janssen’s efforts to transform the health of people in the U.S. and Canada facing cancer, autoimmune disease, heart disease and diabetes, infectious diseases including HIV, pulmonary arterial hypertension, and serious mental illness.In his 30-year career at Janssen, White has led some of the company’s most significant businesses across multiple serious disease areas. He is a results-focused leader, widely respected for his strategic insight and commitment to developing high-performing, diverse teams.As President, Janssen U.S. Immunology, White led Johnson & Johnson’s largest business, making a significant difference for people with debilitating autoimmune diseases through highly impactful medicines and innovative patient support and access programs. Prior to his Immunology role, he was President of Janssen U.S. Oncology. Under White’s leadership, Janssen launched two transformational cancer treatments making Janssen Oncology one of the fastest growing oncology businesses in the U.S. Previously, he held the position of Vice President, Strategic Customer Group, serving all Janssen U.S. businesses, where he led contracting and account management. In this critical role, he served as the market access leader to ensure people who need our medicines have access to them.White represents Johnson & Johnson on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations.He holds a Bachelor of Arts from Rutgers, The State University of New Jersey, where he double-majored in molecular biology and philosophy. He also received a Master of Business Administration from the University of Phoenix.

Peter Guenter is a member of the Executive Board of Merck and CEO of Healthcare. He joined Merck in January 2021.Before joining Merck, Guenter served as CEO of Spanish pharma company Almirall from 2017 to 2020. Prior to that, he spent 22 years at Sanofi, serving as a member of the Executive Committee since 2013. In his most recent role at Sanofi, he served as executive vice president of the company’s Global Diabetes and Cardiovascular unit. Previous roles with Sanofi included responsibility for Global Commercial Operations, Emerging Markets, as well as various marketing, regional and country management roles.Guenter holds a master’s degree in physical education from the Faculty of Medicine and Health Sciences of the University of Ghent.

Robert “Bob” Ingram (1942-2023) was General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of Glaxo/Wellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram was Chairman of the boards of BioCryst Pharmaceuticals, Novan, a late-stage pharmaceutical company focused on dermatology, and Viamet Pharmaceuticals, a private company focused on anti-infective research. He also served as the Lead Director on the board of Cree. In 2013, Mr. Ingram received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors.At the request of President George H.W. Bush, Mr. Ingram formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. In 2014, he received the North Carolina Award for Public Service, the highest civilian honor the state can bestow on an individual. Mr. Ingram served on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GlaxoSmithKline Foundation.Mr. Ingram was a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation. He graduated from Eastern Illinois University with a BS degree in Business Administration.

Robert A. Bradway is Amgen’s chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company’s president and chief operating officer from May 2010 to May 2012, and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010.Prior to joining Amgen, he was a managing director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.He served as the chairman of the CEO Roundtable on Cancer from 2015 up until 2022. Amgen has been a member of the CEO Roundtable on Cancer since 2014, the same year the company earned Gold Standard Accreditation in the US. Amgen earned Gold Standard accreditation in China in 2017. The company also has been a data contributor to Project Data Sphere since 2015.He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university. He is a member of the American Heart Association CEO Roundtable on Cancer, which is helping the Association meet its goal of improving the cardiovascular health of all Americans. He is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors. He also sits on the board of directors for both Boeing and the Norfolk Southern Railway Corporation.Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.

Dr. Martin J. Murphy in 1999 accepted the challenge from President George H. W. Bush to help create and lead what would become the CEO Roundtable on Cancer as its Founding Chief Executive Officer, a role he which he served for the next two decades. He became Emeritus Director of the CEO Roundtable on Cancer’s Board of Directors in 2020. He is Founding CEO of Shanghai TuoXin Health Promotion Center, the CEO Roundtable’s independent China counterpart.Dr. Murphy was also Founding CEO of Project Data Sphere, LLC, a non-profit enterprise devoted to cancer clinical trial data-transparency, data-sharing and data-analysis originally developed by the CEO Roundtable on Cancer. He retired from its Board of Directors in 2020.Dr. Murphy is a member of the National Cancer Policy Forum of the National Academy of Medicine of the U.S. National Academy of Sciences; director emeritus of the Foundation for the National Institutes of Health (FNIH). He is a Fellow of the American Society of Clinical Oncology (ASCO), Co-Chairman of the Strategic & Scientific Advisory Council of the COVID-19 International Data Alliance (ICODA), member of the Global Health Forum, Boao Forum for Asia, and founding editor of three international peer-reviewed biomedical journals: The Oncologist, Stem Cells and Stem Cells Translational Medicine.Co-founder of the Society for Translational Oncology; a member of the Scientific Advisory Board of Hatteras Venture Partners; a charter member of the International Advisory Board of the VU University Medical Imaging Center (Amsterdam); a charter member of Queen’s University Belfast School of Medicine International Review Board, Dr. Murphy is also chairman emeritus of Conquer Cancer, the ASCO Foundation; convener of ACT-China; and Steering Committee member of the Chinese Society of Clinical Oncology (CSCO). He is Senior Oncology Consultant to China’s National Medical Products Administration (NMPA). In November 2021 he was an invited delegate to the Bloomberg New Economy Forum (Singapore) that launched the International Cancer Coalition. He is a director of the Sino-American biotech, Brii Biosciences, Inc. (Hong Kong Stock Exchange, 2137), and a director of Helsinn-China, Ltd. Dr. Murphy is the 2022 recipient of the Ellis Island Medal of Honor bestowed on those who have, “shown the best of America by outstanding commitment to serving our nation professionally, culturally and civically.”

William C. Weldon is Chairman of the Board of Johnson & Johnson. He assumed his current responsibilities in April, 2002. Previously Bill served as Worldwide Chairman, Pharmaceuticals Group, and a Vice Chairman of the Board of Directors. He was elected to the Board in February 2001.Bill joined Johnson & Johnson in 1971 in the sales and marketing department of its McNeil Pharmaceutical subsidiary. In 1982 he was named manager, ICOM Regional Development Center in Southeast Asia. Bill was appointed executive vice president and managing director of Korea McNeil, Ltd., in 1984 and managing director of Ortho-Cilag Pharmaceutical, Ltd., in the U.K. in 1986. In 1989, he was named vice president of sales and marketing at Janssen Pharmaceutica in the U.S., and in 1992 he was appointed president of Ethicon Endo-Surgery.In 1995, Bill was named a company group chairman of Johnson & Johnson and Worldwide Franchise Chairman of Ethicon Endo-Surgery, the Johnson & Johnson affiliate that develops new procedures for minimally-invasive surgery and designs related products. In 1998, Bill was promoted to the Executive Committee and named Worldwide Chairman, Pharmaceuticals Group.Among his outside activities, Bill is a member of the Board of Directors of JPMorgan Chase & Co and the US – China Business Council. He is also the immediate past Chairman of the CEO Roundtable on Cancer, a member of The Business Council, and a member of the Healthcare Leadership Council.Bill also serves as a member of the Board of Trustees for Quinnipiac University. He previously served as Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). Bill was born in Brooklyn, NY, and is a graduate of Quinnipiac University in Hamden, Connecticut. He and his wife have two children.Caring for the world, one person at a timeTM… inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Brian Alexander, MD, was named Chief Executive Officer of Foundation Medicine in March 2021. He previously served as the company’s Chief Medical Officer, and practiced radiation oncology specializing in neuro-oncology at Dana-Farber Brigham Cancer Center. He is also a Senior Lecturer at Harvard Medical School.Dr. Alexander joined Foundation Medicine in September 2018 as a Senior Vice President of Clinical Development, and has since played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine secured FDA approval of its liquid biopsy test, FoundationOne Liquid®CDx, issued its one millionth patient report and launched the company’s personalized circulating tumor DNA (ctDNA) monitoring assay, FoundationOne®Tracker.He was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, 2021, 2022 and 2023.Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs (VA), where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design.Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.

Emily Morris-McCarthy is the general manager, head U.S. oncology for Sanofi. She previously served as franchise head for alliance/immuno-oncology and senior director of marketing for U.S. immuno-oncology marketing at Sanofi. Before coming to Sanofi, she was senior director of U.S. oncology marketing for EMD Serono. She earned a master of arts degree from La Salle University and a bachelor of arts degree from the Massachusetts College of Liberal Arts.

Stu Bailey is senior vice president, head of clinical measurement sciences at EMD Serono, Inc.. He previously served as vice president, head of analytics and data sciences at Biogen and global head of early development biostatistics at Novartis Institutes for Biomedical Research. He holds a DPhil in Mathematics from the University of Sussex.

Dr. Peter Sandor has 25 years of biopharmaceutical leadership experience and currently serves as the senior vice president, Primary Focus Lead, Primary Focus Immuno-oncology at Astellas.In his role, Dr. Sandor has responsibility for leading the strategic direction of Astellas’ early immuno-oncology research and development pipeline and plays an integral role in the expansion of Astellas’ presence in oncology. Dr. Sandor has previously served as vice president, Head of Marketing Strategy, Oncology at Astellas.Prior to Astellas, he was Head of Global Marketing Oncology at Amgen, held several global leadership positions at Bayer Healthcare, led the global launch of a key oncology compound for Berlex and held multiple marketing roles with Schering AG in Germany and Hungary, respectively. Dr. Sandor began his career in academia as a scientific advisor to the Hungarian Academy of Sciences. He earned his Doctor of Medicine at the University of Pécs, Hungary, his Master of Business Administration from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his Postgraduate Degree in Marketing from the University of Pécs, Hungary.

Dr. Eliav Barr became head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), in April 2022. Previously he was Senior Vice President, Global Clinical Development and he has held positions of increasing responsibility including leadership roles in oncology and infectious diseases clinical development. Barr oversaw the company’s Vaccines/Infectious Disease area during a period of high productivity, including the development of novel therapies for chronic hepatitis C and HIV-1 infections. Most recently he led MRL’s Global Medical Affairs organization from 2018 to January 2022, significantly expanding Merck’s scientific engagement and implementation efforts in oncology, vaccines and more. In his latest role Barr leads all late-stage clinical development for Merck’s expansive human health portfolio and pipeline.Barr led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV.Barr is a cardiologist by training. He received his undergraduate degree from Penn State University and his medical degree from Sidney Kimmel Medical College, Thomas Jefferson University. He completed his Internal Medicine residency and Cardiology Fellowship at Johns Hopkins University, and subsequently pursued post-doctoral training at the University of Michigan. Prior to joining Merck in 1995, he held a faculty position at the University of Chicago. In 2019, he received a Penn State Alumni Fellow Award for his dedication to the development of medicines and vaccines that treat and prevent infectious diseases.

Jean-Charles Soria is Amgen’s Senior Vice President of Oncology within Global Development. Soria joined Amgen from Institut Gustave Roussy, where he was appointed director general by France’s Minister of Health and Solidarity.Soria is a medical oncologist and professor of medicine at Paris-Saclay University. He holds a doctorate in molecular biology. He completed his training during a two-year appointment at the MD Anderson Cancer Center in Houston, Texas, U.S., where he was an associate professor from 2013 to 2017. He also served as the director of the Gustave Roussy SIRIC Socrate (Integrated Cancer Research Site) from 2012 to 2017.From 2017 to 2019 he held the role of senior vice president, Research and Development in Oncology, with AstraZeneca in Gaithersburg, Maryland, U.S., where he led research teams responsible for strategy and for development of new agents in immuno-oncology, cell therapy and conjugated antibodies. Additionally, he has authored or co-authored more than 670 articles in leading international journals and has appeared on lists of the most influential research scientists in the world.

Tara Frenkl, MD, MPH is the Head of Oncology Development at Bayer’s Oncology Strategic Business Unit. Prior to joining Bayer, she held the role of Senior Vice President, Head of Medicine Development Leaders in Oncology at GlaxoSmithKline, with strategic impact on the global development of medicines across the company’s oncology portfolio. Prior to joining GlaxoSmithKline, Tara Frenkl was at Merck & Co., Inc. for 13 years in roles of increasing responsibility.

Craig Tendler, M.D. is Vice President and Global Head of Clinical Development, Diagnostics, and Medical Affairs for the Oncology Therapeutic Area at Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. In this position, he is responsible for creating and overseeing robust development plans, including optimal integration of biomarkers and diagnostics, and comprehensive data generation activities for all products in the oncology portfolio, from proof of concept through registration and lifecycle management. He works closely with teams in early development and the disease areas of focus to implement a seamless end-to-end oncology clinical research strategy that incorporates compelling science, broad clinical trial access to diverse populations, and addresses areas of high unmet medical need.Prior to this role, Craig served as Vice President of Medical Affairs for Tibotec Therapeutics and then Ortho-Biotech, where he led medical affairs teams in lifecycle management and data generation for the Janssen Virology and Oncology franchises.Craig has overseen and coordinated more than 30 major drug approvals by national regulatory agencies, including at least ten NDAs by the US Food and Drug Administration (FDA). He and his have team worked in collaboration with the FDA and the European Medicines Agency to secure the worldwide approvals of Janssen’s treatments in prostate cancer, hematologic malignancies, as well as for lung and bladder cancer. Further, together with his team, Craig has been instrumental in achieving 11 FDA breakthrough designations for accelerating the early development of promising investigational medicines intended for the treatment of serious oncology conditions.Prior to joining Janssen, Craig served as the Vice President of Oncology Clinical Research and Chair of the Oncology Licensing Committee at the Schering-Plough Research Institute. In addition to his pharmaceutical industry experience, he has served as Assistant Professor of Pediatrics/Hematology-Oncology at the Mount Sinai School of Medicine in New York City and as a research fellow at the National Cancer Institute in Bethesda, Maryland.Craig earned his undergraduate degree from Cornell University, and graduated from the Mount Sinai School of Medicine, New York City, with high honors and induction into the Alpha Omega Alpha Medical Society.

Dr. Otis Brawley is a globally recognized expert in cancer prevention and control. He has worked to reduce over screening of medical conditions, which has revolutionized patient treatment by increasing quality of life and reducing health disparities.Dr. Brawley’s research focuses on developing cancer screening strategies and ensuring their effectiveness. He has championed efforts to decrease smoking and implement other lifestyle risk reduction programs, as well as to provide critical support to cancer patients and concentrate cancer control efforts in areas where they could be most effective.Dr. Brawley currently leads a broad interdisciplinary research effort on cancer health disparities at the Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, striving to close racial, economic, and social disparities in the prevention, detection, and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland.He joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the American Cancer Society and Emory University. He also is a former member of the FDA Oncologic Drug Advisory Committee (ODAC).Dr. Brawley is a current member of the National Cancer Institute’s (NCI) Board of Scientific Counselors. Formerly, Dr. Brawley was a professor in the Department of Hematology and Oncology at the Emory University School of Medicine. He was also previously a senior investigator at the National Institute of Health (NIH) and NCI. In 2013, he was the recipient of a Special Recognition Award from the American Society of Clinical Oncology.Dr. Brawley received an M.D. from the University of Chicago, Pritzker School of Medicine. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the NCI. He is board certified in internal medicine and medical oncology.

David is responsible for leading the Global Occupational Health function at Bristol Myers Squibb. His previous roles were with Rolls-Royce (aerospace and defense) Rio Tinto (mining) and GlaxoSmithKline (pharmaceuticals).David is a practising physician and is a Fellow of the Royal College of Physicians, the Faculty of Occupational Medicine and the American College of Occupational and Environmental Medicine. His special interests include health equity; the intersection between climate and health; workplace mental health and wellbeing and workforce wellbeing as an enabler to enhance engagement, productivity, and performance.

Ron Goetzel wears two hats. He is Senior Scientist and Director of the Institute for Health and Productivity Studies (IHPS) at the Johns Hopkins Bloomberg School of Public Health and Vice President of Consulting and Applied Research for IBM Watson Health. The mission of the IHPS is to bridge the gap between academia, the business community, and the healthcare policy world – bringing academic resources into policy debates and day-to-day business decisions, and bringing health and productivity management issues into academia.Before moving to Johns Hopkins University, Dr. Goetzel was on the faculty at Emory and Cornell Universities. Dr. Goetzel is responsible for leading innovative projects for healthcare purchaser, managed care, government, and pharmaceutical clients interested in conducting cutting-edge research focused on the relationship between health and well-being, medical costs, and work-related productivity. He is an internationally recognized and widely published expert in health and productivity management (HPM), return-on-investment (ROI), program evaluation, and outcomes research. Dr. Goetzel has published well over 200 peer-reviewed articles and book chapters and frequently presents at international business and scientific forums.

Dr. Marcelo Targino is responsible for the Corporate Medical Team and the Executive Health program providing medical care and support for all executives and senior leaders across the enterprise at Johnson & Johnson. He is also responsible for staying ahead of the rapid changes in medicine and technology with the goal of maintaining the healthiest workforce, and positioning Johnson & Johnson as the global thought leader in health and well-being. Additionally, Dr. Targino provides support to Johnson & Johnson Health and Wellness Solutions, Inc.Dr. Targino joined Johnson & Johnson five years ago as part of the Global Health Services Occupational Health Team. He was responsible for the deployment and performance of GHS strategy, policies, standards and compliance across the Americas in the areas of occupational health and workplace health risk management. He also provided clinical services at several J&J locations in New Jersey.Dr. Targino also works as a Hospital Medicine Specialist, with a focus on critical care medicine at Doylestown Hospital, in Pennsylvania. He is Board Certified in Occupational and Environmental Medicine, Internal Medicine and Clinical Informatics. He obtained his Bachelor of Science from the Massachusetts Institute of Technology, his medical degree from the University of South Florida and his Master in Public Health from Harvard University. He is a fellow of the American College of Occupational and Environmental Medicine, and the American College of Physicians.

Brian Kehan is a dedicated and knowledgeable leader in the field of benefits and wellbeing. As the Director of Benefits and Well-being at Merck & Co., Inc, he oversees the company’s comprehensive benefits program, which includes health, retirement, and wellness benefits. With over 15 years of experience, Brian has developed a deep understanding of the complex and ever-changing landscape of benefits and wellbeing. He is known for his ability to design and implement innovative programs that meet the needs of employees while also aligning with the company’s overall business strategy.Prior to joining Merck & Co., Inc, Brian held management roles in benefits and wellbeing at several other companies in various industries. In these roles, he led the development and implementation of successful benefits programs and was responsible for managing vendor relationships, analyzing data, and ensuring compliance with regulatory requirements.Brian holds a bachelor’s degree in Labor Industrial Relations from the Pennsylvania State University and completed the Certified Employee Benefits Specialists (CEBS) designation

Aubrey Van Kirk Villalobos, DrPH, MEd, is a Health Scientist with the Implementation Science (IS) Team in the Office of the Director in the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). In this role she leads efforts to advance the involvement of practitioners in IS to enhance the integration of evidence-based guidelines, programs, and policies for cancer control in public health and clinical practice. Dr. Villalobos cultivates research-practice partnerships through participation in the Comprehensive Cancer Control National Partnership, Cancer Prevention and Control Research Network, and the Consortium for Cancer Implementation Science, and serves as an advisor on the Evidence Based Cancer Control Programs website and the Healthy People 2030 cancer workgroup.Prior to joining the NCI, Dr. Villalobos served as director of cancer control and health equity at the George Washington University (GW) Cancer Center where she supported strategic planning for the center’s community outreach and engagement activities and directed a multi-million-dollar portfolio of sponsored projects providing technical assistance and training to public health and health care professionals. Previously, she served as the cancer education outreach coordinator in the international outreach program at St. Jude Children’s Research Hospital.Dr. Villalobos’s scientific and programmatic interests include social and structural influences on health behaviors and inequities, particularly related to primary cancer and chronic disease prevention and early detection. Her mixed methods dissertation research focused on social norms and breastfeeding among African American women and was supported by fellowships from the Sumner M. Redstone Global Center for Prevention and Wellness and the Jacobs Institute of Women’s Health Clara Schiffer Project. She has expertise in social/behavioral science; community engagement and partnership-building; policy, systems, and environmental change for health promotion; and clinician, professional, patient and community education.Dr. Villalobos received a Doctor of Public Health in health behavior from the Milken Institute School of Public Health at the George Washington University in Washington, D.C., where she also earned a Master of Public Health in health promotion. She holds a Master of Education from Christian Brothers University in Memphis, TN and a Bachelor of Science in biological chemistry from Bates College in Lewiston, ME.

Jennifer Mills, PhD, MSW, MPH was named Vice President, Medical Affairs at Foundation Medicine in July 2022. She has two decades of experience building impactful partnerships across the nonprofit, industry and academic communities. In her current role, Jen leads the Medical Affairs team to enable and inform healthcare providers in their treatment decision-making, and to empower people impacted by cancer. She fosters innovative partnerships across the oncology community and helps drive her team’s efforts to make molecular profiling an indispensable tool for cancer care and research.Jen joined Foundation Medicine in 2018 as Vice President, Patient and Professional Partnerships, where she built the company’s long-term engagement strategy with several critical segments of the oncology community. Her leadership resulted in deeper relationships with key oncology stakeholders, including societies, patient advocacy organizations, key institutions and individual influencers, and she also led development of several new, enduring engagement models.Prior to joining Foundation Medicine in 2018, Jen spent eight years at Genentech leading various advocacy and alliance initiatives, including leading the U.S. effort to advance Genentech’s approach to patient engagement across the lifecycle and build novel patient-focused partnerships. She was also the co-founder of Genentech’s Advancing Inclusive Research effort.Earlier in her career, Jen spent nearly a decade at the Lymphoma Research Foundation, where she oversaw nationwide programs and services for patients and caregivers. Jen’s oncology experience began in 1999 on the bone marrow and stem cell transplantation service at New York Presbyterian Hospital, where she provided direct patient care and created new programs to increase social connectedness through technology. She began her career in eastern Alabama with a focus on HIV/AIDS outreach and awareness efforts.Jen received her PhD in social work from New York University, where she also served as an Adjunct Professor. Her dissertation research focused on the cycle of relapsed/refractory disease among young adults diagnosed with lymphoma. She holds a bachelor’s degree from Auburn University, a Masters of Social Work from Columbia University, and a Masters of Public Health from New York University, where she also completed a Post-Master’s Fellowship in End of Life and Palliative Care.

Since 2009, Major General Granger has been the President and CEO of THE 5Ps, LLC, a health care, education, and leadership consulting organization in Colorado. Prior to his retirement from the US Army in 2009, Dr. Granger served as the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, DC.In that role, he was the principal advisor on health plan policy and performance at the Department of Defense. His experience, background, training, and expertise has required the building of strong, value-based relationships. He acquires clear guidelines to assess and determine “best value” and determines a process to ensure clear requirements and criteria to manage relationships to measurable, accountable outcomes.Dr. Granger oversaw the acquisition, operation, and integration of TRICARE/DOD’s managed care program within the Military Health System, leading a staff of 1,800 in planning, budgeting, and executing a $22.5 Billion Defense Health Program.Prior to joining TRICARE Management Activity, MG Granger led the largest U.S. and multi-national battlefield health system in our recent history while serving as Commander, Task Force 44th Medical Command and Command Surgeon for the Multinational Corps Iraq. He has led at every level of the Army Medical Department, with previous assignments across the United States, Europe, and Iraq.Dr. Granger has received numerous awards, decorations, and honors, including the Defense Superior Service Medal, the Legion of Merit with three oak leaf clusters, the Bronze Star Medal, and the Meritorious Service Medal with four oak leaf clusters. He is board-certified by the American Board of Internal Medicine and the Board of Hematology and Oncology, certified Physician Executive by the Certifying Commission in Medical Management, certified by the American College of Healthcare Executives, and Certified in Medical Quality by the American Board of Medical Quality. CERT-certificate in Cybersecurity Oversight from Carnegie Mellon University, certified in Healthcare Compliance by HCCA and is a certified Compliance Officer by AAPC.

Dr. Otis Brawley is a globally recognized expert in cancer prevention and control. He has worked to reduce over screening of medical conditions, which has revolutionized patient treatment by increasing quality of life and reducing health disparities.Dr. Brawley’s research focuses on developing cancer screening strategies and ensuring their effectiveness. He has championed efforts to decrease smoking and implement other lifestyle risk reduction programs, as well as to provide critical support to cancer patients and concentrate cancer control efforts in areas where they could be most effective.Dr. Brawley currently leads a broad interdisciplinary research effort on cancer health disparities at the Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, striving to close racial, economic, and social disparities in the prevention, detection, and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland.He joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the American Cancer Society and Emory University. He also is a former member of the FDA Oncologic Drug Advisory Committee (ODAC).Dr. Brawley is a current member of the National Cancer Institute’s (NCI) Board of Scientific Counselors. Formerly, Dr. Brawley was a professor in the Department of Hematology and Oncology at the Emory University School of Medicine. He was also previously a senior investigator at the National Institute of Health (NIH) and NCI. In 2013, he was the recipient of a Special Recognition Award from the American Society of Clinical Oncology.Dr. Brawley received an M.D. from the University of Chicago, Pritzker School of Medicine. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the NCI. He is board certified in internal medicine and medical oncology.

Fields Jackson, Jr. is currently the CEO and Chief Cheerleader of Racing Toward Diversity Magazine, Cary, NC. Racing Toward Diversity is a quarterly magazine that showcases the best diversity efforts and initiatives being made today. Written with business and educational audiences in mind, its stories reach an estimated 3.5 million readers through the publication, newspaper, blog and associated social media.Jackson also is President of the College Diversity Network; Adjunct professor at Shaw University in Raleigh, NC; Distinguished Visiting Professor at South Carolina State University in Orangeburg, SC; and former Executive Director of the HBCU Business Dean Roundtable.He was recognized by Diversity Best Practices as one of the Top Diversity Thought Leaders on Twitter (https://www.diversitybestpractices.com/news-articles/top-diversity-thoug…) and has been identified as #13 of the top 100 global influencers focusing on Gender Equality and Diversity (http://bit.ly/2HD46LD) by Onalytica, a London-based company that helps run influencer programs for some of the largest brands in the world.Hive Learning recently recognized Jackson as one of the Most Influential Diversity &Inclusion Leaders – 2019. Hive said Jackson is an influential Diversity and Inclusion advocate and expert who advocates that job seekers conduct their due diligence in finding diverse workplace opportunities through research, networking and asking the right questions. (http://bit.ly/35QiQAM)Jackson received his Bachelor of Arts Degree in Economics and Bachelor of Arts Degree in Philosophy from Allegheny College, Meadville, PA, and an MBA from Northern Illinois, DeKalb, Ill.

Dr. Robert (Bob) J. Brown is CEO & Founder of B&C International, a global business management consulting firm headquartered in High Point, NC. He is also founder of the International BookSmart Foundation, a nonprofit that to date has shipped over 5 million books, countless teachers’ supplies and opened over 300 libraries on the continent of Africa.Dr. Brown, a trusted advisor to the most influential individuals, corporations and movements of the 20th and 21st centuries, was born on February 26, 1935 in High Point, North Carolina. He entered the field of law enforcement in 1956, serving first as a police officer for the City of High Point and then as a highly regarded federal agent with the U.S. Department of the Treasury focusing on federal narcotics cases. In 1960, Dr. Brown left the Bureau to return to High Point NC and open B&C Associates a public relations company.As a pioneer in crisis management, multi-cultural communication and race relations, Dr. Brown advised, traveled with, and raised money for the late Dr. Martin Luther King, Jr.; was a member of the corporate plans board of Carl Byoir & Associates (the largest public relations firm in the world at the time), and was a close friend and confidant to the Mandela family. Early in his PR career he was contracted by F.W. Woolworth Corporation, A&P Supermarkets, Wrangler, Sara Lee, SC Johnson and Kimberly-Clark, to handle corporate communications and race relations during pivotal moments of the civil rights movement.In the political arena, Dr. Brown worked as the Director of Information and Research for the young Democrats of New York City in the presidential campaign of Senator John F Kennedy. In 1964, he assisted in the election of Robert F. Kennedy into the United States Senate and also assisted in his presidential bid. In 1968, he took a leave of absence from B&C Associates to serve as Special Assistant to President Richard Nixon after helping him win 21% of the African-American vote during his campaign (a level unmatched by the Republican Party to date). While in that position, his responsibilities included community relations, civil rights, emergency preparedness, small towns, and day care. Dr. Brown has since been applauded for using his ability to marry great strategies with an ability to develop relationships, and has been credited with starting and developing the U. S. Minority Enterprise Program and initiating the U. S. Government Black College Program through Executive Order by President Richard Nixon.In 1980, Dr. Brown founded B&C International (BCI), Inc. which is now one of the oldest and most widely respected minority-owned strategy and business management consulting firms. BCI one of the world’s leaders in addressing critical issues, identifying high value opportunities, and implementing sustainable process innovations through communication, cultural, and operational advancements.Proclaimed by The Washington Post as a “World Class Power Broker”, Dr. Brown has a long legacy of service & counsel to corporate, educational, and civic organizations. He currently serves as a member of the boards of AutoNation, Inc. and Blue Ridge Holdings, Inc. He has also served on the boards of the NCAA, Duke Energy, Wachovia Corporation, Wake Forest University Baptist Medical Center, and Sonoco Products Company.As a strong supporter of youth, education, and non-violent programs, Dr. Brown serves on the boards of High Point University, Boston University, Virginia Union University, National Urban League, Horatio Alger Association, and the Richard Nixon Foundation.Numerous colleges, universities and national organizations have honored Dr. Brown. He holds ten honorary doctorate degrees and six national achievement awards. He has also been honored as a recipient of the Horatio Alger Association of Distinguished Americans Award, the Small Business Administration’s Lifetime Achievement Award, the United Way of Greater High Point’s 2002 Alexis de Tocqueville Society Award, The High Point Enterprise 2005 Citizen of the Year Award, the U.S. Department of Commerce’s Minority Business Development Agency’s 2006 Abe Venable Legacy Award for Lifetime Achievement, the U.S. Department of Commerce Minority Business Development Agency’s 2007 National Director’s Legacy Award for Lifetime Achievement and the National Urban League’s 2009 Collins Award. Additionally, he is the recipient of the 2010 Executive Networking Conference Trailblazer Award, named in his honor.Dr. Brown currently resides in High Point, North Carolina.

Dr. Marelli Colon Emeric is a child and adolescent psychiatrist. Dr. Colon graduated Magna Cum Laude from the University of Puerto Rico. She obtained her medical degree from the University of Puerto Rico School of Medicine. She started her training in psychiatry at the University of South Florida College of Medicine and completed her child and adolescent psychiatry training at Emory University School of Medicine. She has over 20 years of experience working in clinical research and has actively participated in the translation and validation of psychiatric scales.Dr. Colon has extensive experience working with children, adolescents and adults in different settings including hospitals, residential treatment facilities, juvenile justice system and the courts. She has given many interviews, conferences and workshops on a variety of topics on mental health, stress management, pain management, emotional aspects of cancer and chronic diseases, team building, wellness and mindfulness. In accordance with her commitment to the community she currently belongs to the Tiffany Circle of the American Red Cross, chapter of Puerto Rico.

Joya Delgado-Harris joined the CEO Roundtable on Cancer in June as Executive Director for the Gold Standard, inclusive of our Health Equity and Going4Gold initiative.Joya previously was the Director of Research Integration for the American Cancer Society. In that role, she provided oversight and management of the integration of products and outcomes stemming from the Office of Cancer Research and Implementation into enterprise-wide mission objectives.Past areas of work for Joya include program development, curriculum design, grant-writing, engaging board members and volunteers as well as developing business partnerships. In addition to the American Cancer Society, she has worked for Y-ME National Breast Cancer Organization, Executive Director for the Association of Village PRIDE, and Director of Product Development for the Metropolitan Atlanta Chapter of the American Red Cross.As a breast cancer survivor, Joya serves as a Consumer Advocate Peer Reviewer for the Congressionally Directed Medical Research Programs (CDMRP), administered by the Department of Defense, sitting alongside scientists to review and evaluate innovative breast cancer research grant proposals. She also serves as a reviewer for the Cancer Prevention and Research Institute of Texas (CPRIT).After earning a BA from Wellesley College, Joya received a Master of Public Health degree with concentration in public health policy and management from the Rollins School of Public Health of Emory University.

Dr. Cynthia Warrick served as the first female President for Stillman College, a Historically Black (HBCU) liberal arts college in Tuscaloosa, Alabama. A pharmacist and health services researcher, Dr. Warrick has been an NIH-funded investigator since 2001. Named one of the Ten Most Dominant HBCU Leaders of 2023 by the HBCU Campaign Fund, Dr. Warrick served as the Interim President of Grambling State University and South Carolina State University after advancing the faculty and administrative ranks at Howard University, the University of Texas, Texas Southern University, Florida A&M University, and Elizabeth City State University.She received a PhD in Environmental Science & Policy from George Mason University, an MS in Public Policy from the Georgia Institute of Technology, and a BS in Pharmacy from Howard University. In 2016, she founded the Society for Diversity in the Biomedical Sciences, to facilitate career pathways of underrepresented students into NIH-funded biomedical research and graduate programs.

Roberto A. Gonzalez is the founder and principal of RA Gonzalez & Associates, a Veteran Service Disabled, minority-owned small business, and Co – Founder of Cornerstone & Associates LLC, a lobbying and marketing consulting firm based in Washington, D.C. Mr. Gonzalez retired in 1995 from the United States Army with the rank of Lieutenant Colonel after serving 20+ years in the Medical Services Corp. While in the Army, he served at various levels of management and responsibility, including a position as the Military Assistant and Senior Advisor to two Assistant Secretaries of Defense for Health Affairs. Those posts included the management of the Nations’ second largest integrated health care system. The office is accountable for over $35 billion annually, including the responsibility for providing access, in both peacetime and during war, to more than 8.5 million DOD beneficiaries, with a worldwide network of 128 hospitals, in excess of 800 medical and dental clinics, and a $3.5 billion indemnity health insurance program. He has also been involved in international assistance programs and interagency collaborative projects.Mr. Gonzalez also served as the liaison to and coordinator with the Office of the Under Secretary of Health Administration, Department of Veterans Affairs, the Services’ Surgeon General’s Offices, Department of Health and Human Services and Medical Directorate at both the U.S. State Department and U.S. Congress.Since his retirement from the U.S. Army, Mr. Gonzalez has worked with the Government of Puerto Rico, private healthcare sector companies and Academic Health institutions under the Affordable Care Act and the Health Reform initiatives for Health Informatics. He was successful in delivering over $30 million in grant funds from the Office of the National Coordinator at CMS and has worked with the government of Puerto Rico to develop its strategy for conducting a health analysis of the residents of Vieques, Puerto Rico, relating to the health effects on them related to the US Navy’s bombing of the island in the 1970s-1990s.Recently following Hurricane Maria’s devastation of Puerto Rico in September 2017, Mr. Gonzalez was appointed as Special Advisor to the Secretary of Health in Puerto Rico, and Liaison and Chief Coordinator to the Centers for Disease Control for CRISIS supplemental fund of $41 million, covering some 33 public health projects.Fluent in Spanish, Mr. Gonzalez has worked and lived in Puerto Rico, Central America, South America and Spain as well as in various cities in the U.S. Mainland.  He is the recipient of numerous awards and honors, including the Expert Field Medical, Airborne and Air assault badges, Defense Superior Service Medal, two Defense Meritorious Service Medals, two Army Meritorious Service Medal, Defense & Army Commendation Medals, and the Order of Military Medical Merit. He is currently an Adjunct Assistant Professor of Military Services at the University of the Health Sciences in Bethesda, Maryland. Mr. Gonzalez is a member of several military and veteran associations and actively supports the RNC, RNHA, and NAUS and has participated and support several Hispanic youth initiatives.

Sean Khozin, MD, MPH, a physician-executive, board-certified oncologist, and data scientist with over 15 years of experience in therapeutic development, drug regulation, and the applications of artificial intelligence and machine learning in biomedical research.As the founder of Phyusion, Dr. Khozin is working on advancing innovations at the intersection of biology, technology, and artificial intelligence. He is the former Chief Executive Officer of CancerLinQ, a precision oncology enterprise focused on transforming cancer care and research with real-world data and advanced analytics. He was previously the Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative new medicines and vaccines. Prior to this, he was a founding member of the US FDA’s Oncology Center of Excellence and Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that he established under special federal authorities. As a uniquely entrepreneurial sandbox housed within the agency responsible for regulating nearly a third of the US economy, INFORMED played a pivotal role in shaping the US FDA’s position on real-world evidence and catalyzing the use of novel data science solutions in drug discovery and clinical development.Before his tenure in the US federal government, Dr. Khozin was the cofounder of Hello Health, a pioneering TechBio company developing telemedicine, point-of-care data visualization, and advanced analytical systems as an integrated approach to optimizing drug discovery, patient care, and clinical research. The company’s core technology offerings were first operationalized in a multidisciplinary network of clinics he had founded called SKMD.Dr. Khozin is a Research Affiliate at the MIT Laboratory for Financial Engineering, where he combines his quantitative and life sciences expertise in support of novel solutions for improving the lives of patients with high unmet medical need. He has over a decade of clinical and basic science research experience at the US National Cancer Institute, having started his clinical work developing new molecular profiling methods in thoracic malignancies.

Jon McDunn, PhD, is president of Project Data Sphere, an independent initiative of the CEO Roundtable on Cancer focused on fighting cancer through open-access data sharing and oncology-focused research program initiatives. Previously he was Executive Director of the External Control Arm (ECA) Program and Business Development. The ECA program is a collaborative effort of clinicians, trialists, biostatisticians, and data scientists to use existing clinical data to accelerate and strengthen evidence generation in clinical development. Jon is also the scientific and technical lead for strategic alliances and business development. In this capacity, he scouts and evaluates collaborative opportunities with new and existing partners.Before joining PDS in 2020, Jon built a startup company, Clinical Sensors. There he secured $4M in NIH SBIR funding, drove the R&D program, and orchestrated its acquisition. Prior to Clinical Sensors, Jon launched two products for Metabolon, "clinical (GSP) biomarkers as a service" and a multianalyte assay for prostate cancer risk assessment. At the beginning of his career, Jon worked in product development at Incyte Genomics.Jon as held faculty positions at UNC-Chapel Hill (Biomedical Engineering) and Washington University in St. Louis (Anesthesiology). Jon was a postdoctoral fellow in surgical critical care at Washington University in St. Louis; and received in PhD in inflammation biology from The Scripps Research Institute and BS in chemistry from the California Institute of Technology. He has published over 50 peer-reviewed manuscripts and was part of the team that developed the foundational IP for Accuronix.